Oct 24, 2019 / 12:00PM GMT
Operator
Ladies and gentlemen, welcome to the XVIVO Perfusion Third Quarter 2019 Report Webcast. Today, I am pleased to present Magnus Nilsson, CEO; and Christoffer Rosenblad, CFO.
I will now hand you over to Magnus Nilsson. Sir, please go ahead.
Magnus Nilsson - Xvivo Perfusion AB(publ)-CEO&MD
Thank you and welcome to the 28th quarterly report of an independent XVIVO Perfusion. And this is, as we said, the interim report for the third quarter.
Next slide, please. So the highlights. It's been an important quarter for us, and I'll try to put you into the picture.
Q3, first time, rolling 12 months nondurable sales over SEK 200 million. We have received a patent approval for the Perfadex Plus, and we have started a very interesting collaboration to develop fast diagnostic tests using biomarkers at -- to be used in EVLP and similar.
And repeating for the full year, the most important highlights is, of course, the PMA for XPS and STEEN Solution, the patents for the heart preservation
Q3 2019 Xvivo Perfusion AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
